AstraZeneca PLC said Thursday Phase 3 trials on its AZD7442 antibody combination confirmed that the treatment reduces risk of developing symptomatic Covid-19.
from MarketWatch.com - Top Stories https://ift.tt/3crdX5P
via IFTTT
from MarketWatch.com - Top Stories https://ift.tt/3crdX5P
via IFTTT
Kommentare
Kommentar veröffentlichen